Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer

被引：0
|
作者：
Federica Marmorino
Lisa Salvatore
Cecilia Barbara
Giacomo Allegrini
Lorenzo Antonuzzo
Gianluca Masi
Fotios Loupakis
Beatrice Borelli
Silvana Chiara
Maria Chiara Banzi
Emanuela Miraglio
Domenico Amoroso
Francesco Dargenio
Andrea Bonetti
Angelo Martignetti
Myriam Paris
Daniela Tomcikova
Luca Boni
Alfredo Falcone
Chiara Cremolini
机构：
[1] Azienda Ospedaliero-Universitaria Pisana,Department of Medical Oncology
[2] Ospedale Civile di Livorno,Division of Medical Oncology
[3] Pontedera Hospital,Department of Oncology
[4] Azienda Ospedaliero-Universitaria Careggi,undefined
[5] Istituto Oncologico Venoto,undefined
[6] National Institute for Cancer Research,undefined
[7] Arcispedale Santa Maria Nuova,undefined
[8] IRCCS,undefined
[9] S. Croce General Hospital,undefined
[10] Ospedale Versilia–Lido di Camaiore,undefined
[11] Dipartimento oncologico AUSL 6 Livorno–Piombino,undefined
[12] Department of Medical Oncology Mater Salutis Hospital Legnago,undefined
[13] Dipartimento Oncologico AUSL 7,undefined
[14] S.O.C. Oncologia–Ospedale degli Infermi,undefined
[15] Fondazione Sandro Pitigliani,undefined
[16] Clinical Trial Coordinating Center,undefined
[17] AOU Careggi,undefined
[18] Istituto Toscano Tumori,undefined
来源：
British Journal of Cancer | 2017年 / 116卷
关键词：
bevacizumab beyond progression; LDH; predictive marker;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：318 / 323
页数：5
相关论文
共 50 条
  • [41] Excessive collagen turnover products are released during colorectal cancer progression and elevated in serum from metastatic colorectal cancer patients
    S. N. Kehlet
    R. Sanz-Pamplona
    S. Brix
    D. J. Leeming
    M. A. Karsdal
    V. Moreno
    Scientific Reports, 6
  • [42] FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer REPLY
    Cremolini, Chiara
    Loupakis, Fotios
    Falcone, Alfredo
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (03): : 291 - 292
  • [43] Bevacizumab in elderly patients with metastatic colorectal cancer
    Sclafani, Francesco
    Cunningham, David
    JOURNAL OF GERIATRIC ONCOLOGY, 2014, 5 (01) : 78 - 88
  • [44] Excessive collagen turnover products are released during colorectal cancer progression and elevated in serum from metastatic colorectal cancer patients
    Kehlet, S. N.
    Sanz-Pamplona, R.
    Brix, S.
    Leeming, D. J.
    Karsdal, M. A.
    Moreno, V.
    SCIENTIFIC REPORTS, 2016, 6
  • [45] Use of bevacizumab in the treatment of metastatic colorectal cancer
    Raouf, Sherif
    Bridgewater, John
    Ellis, Richard
    Ferry, David
    Hill, Mark
    Wasan, Harpreet
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2012, 73 (01) : 25 - 30
  • [46] FOLFOXIRI plus Bevacizumab in metastatic colorectal Cancer
    不详
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, 58 (07): : 630 - 630
  • [47] Visceral fat and bevacizumab in metastatic colorectal cancer
    Jubb, A. M.
    GUT, 2010, 59 (10) : 1449 - 1450
  • [48] Bevacizumab in the therapy for refractory metastatic colorectal cancer
    Mulcahy, Mary F.
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (01): : 53 - 59
  • [49] TREATMENT WITH BEVACIZUMAB IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Cherciu, Nelly
    Petria, Cristina
    ANNALS OF ONCOLOGY, 2012, 23 : 92 - 92
  • [50] Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
    Tol, Jolien
    Koopman, Miriam
    Cats, Annemieke
    Rodenburg, Cees J.
    Creemers, Geert J. M.
    Schrama, Jolanda G.
    Erdkamp, Frans L. G.
    Vos, Allert H.
    van Groeningen, Cees J.
    Sinnige, Harm A. M.
    Richel, Dirk J.
    Voest, Emile E.
    Dijkstra, Jeroen R.
    Vink-Borger, Marianne E.
    Antonini, Ninja F.
    Mol, Linda
    van Krieken, Johan H. J. M.
    Dalesio, Otilia
    Punt, Cornelis J. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (06): : 563 - 572
12345